

WHO REGIONAL OFFICE FOR AFRICA COVID-19 RAPID POLICY BRIEF SERIES

SERIES 14: COVID-19 AND HYPERTENSION

NUMBER 014-01: The effects of COVID-19 on persons living with hypertension

Based on information as at 28 February 2021

Rapid Policy Brief Number: 014-01 - The effects of COVID-19 on persons living with hypertension

WHO/AF/ARD/DAK/37/2021

© WHO Regional Office for Africa 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Rapid Policy Brief Number: 014-01 - The effects of COVID-19 on persons living with hypertension. Brazzaville: WHO Regional Office for Africa; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Designed and printed in the WHO Regional Office for Africa, Brazzaville, Congo

1	RAPID POLICY BRIEF NUMBER: 014-01
2	RESEARCH DOMAIN: COVID-19 AND HYPERTENSION
3	TITLE: The effects of COVID-19 on persons living with hypertension.
4	DATE OF PUBLICATION: 26/03/2021
5	<p>BACKGROUND</p> <p>The COVID-19 pandemic has led to significant morbidity and mortality coupled with severe strain on health systems globally [1]. Although most people recover from the disease, it has been shown that people living with comorbidities such as hypertension, diabetes, and obesity are affected differently from the remaining population [2,3].</p> <p>Therefore, this policy brief aims to summarize evidence on the effects of COVID-19 on persons living with hypertension.</p>
6	<p>SEARCH STRATEGY / RESEARCH METHODS</p> <p>Five databases were searched for studies conducted between December 2019 and February 28, 2021, including PUBMED, WHO COVID-19 database, Cochrane COVID-19 Study Register, and Google scholar. The search terms used were: “hypertension,” “high blood pressure,” “COVID-19”, “SARS-CoV-2”, and “Coronavirus,” using relevant Boolean operators. A further search was done, which included “Africa” and a search string of all countries in Africa to identify studies specific to the continent. A total of 19 articles were used to synthesize findings summarized in this policy brief, and the majority of them were systematic reviews, including meta-analyses.</p>
7	<p>SUMMARY OF GLOBALLY PUBLISHED LITERATURE RELATED TO THE SUBJECT</p> <p>Living with hypertension is associated with worse outcomes from COVID-19 from a systematic review conducted in China, based on April 10, 2020 literature search [4]. In a systematic review of the association of metabolic risk factors and risk of Covid-19, mostly involving studies from the USA and China, hypertension was more seen to be the most prevalent comorbidity (32%) than obesity (29%) and diabetes (22%) [5].</p> <p>A systematic review and meta-analysis of 10,898 patients by Momtazmanesh and colleagues showed that patients with hypertension were more than twice more likely to die from COVID-19 than</p>

	<p>other patients; 3.8 times more likely to be admitted in intensive care units (ICU) and 2.5 times more likely to develop severe COVID-19 infection [2].</p> <p>Dorjee and colleagues, in a systematic review of 77 studies that included 38906 hospitalized patients, demonstrated 50% of hospitalized patients had hypertension. Of all the COVID-19 patients that died, 66% had hypertension [6].</p> <p>Similarly, in the US, 55% of patients who were hospitalized due to COVID-19 had hypertension (55%) [6]</p> <p>Many other studies have shown hypertension to be associated with a higher risk of severe infections and mortality [3,7–15]. Increased mortality among persons with hypertension may be due to the upregulation of Angiotensin-Converting Enzyme 2 (ACE2). However, the reason for the upregulation is still unclear [9].</p>
<p>8</p>	<p>SUMMARY OF AFRICA-SPECIFIC LITERATURE ON THE SUBJECT</p> <p>Evidence from studies reported in Africa suggests that persons living with hypertension are also severely affected [1], just like their counterparts in other parts of the world. A preliminary analysis conducted in 14 countries in Africa showed that hypertension is one of the commonest comorbidities associated with COVID-19 patients [1]. Another study, an epidemiological analysis of COVID-19 related deaths between March and July 2020 in South Africa, showed similar findings among people who died from the disease [16]. Similarly, a surveillance study of COVID-19 hospital admissions among persons living with HIV in South Africa also showed that having hypertension is associated with increased mortality [17].</p> <p>Increased mortality in persons living with hypertension has also been reported in African countries in Africa, including the Democratic Republic of Congo [18], Nigeria [18], and Kenya [19].</p>
<p>9</p>	<p>POLICY FINDINGS</p> <ul style="list-style-type: none"> • Hypertension is one of the most common comorbidities in patients infected with COVID-19. • Strong evidence suggests that persons living with hypertension are at higher risks of developing severe complications from COVID-19, being hospitalized, being admitted to the ICUs, and dying from the disease. • Evidence also suggests an upregulation of ACE2 among COVID-19 with hypertension. This evidence is essential to inform the management of COVID-19 among this category of persons.
<p>10</p>	<p>ONGOING RESEARCH IN THE AFRICAN REGION</p> <p>None found</p>
<p>11</p>	<p>AFRO RECOMMENDATIONS FOR FURTHER RESEARCH</p>

Research is needed on the impact of the COVID-19 pandemic on healthcare services provided to people living with comorbidities, such as hypertension, in Africa.

More research is also required to fully understand the pathophysiology of COVID-19 among persons living with hypertension, especially on the mechanism behind the upregulation of ACE2.

1 REFERENCES

- 2 1. World health organisation (WHO). Noncommunicable diseases increase risk of dying from COVID-19 in Africa | WHO | Regional Office for Africa [Internet]. [cited 2021 March 3]. Available from: <https://www.afro.who.int/news/noncommunicable-diseases-increase-risk-dying-covid-19-africa>
2. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elseyed H, Dalvi B, Malakan Rad E. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. *Egypt Hear J*. 2020;72(1).
3. Bhattacharyya A, Seth A, Srivast N, Imeokparia M, Rai S. Coronavirus (COVID-19): A Systematic Review and Meta-analysis to Evaluate the Significance of Demographics and Comorbidities. *Res Sq [Internet]*. 2021;1–27. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33469575> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7814834>
4. Zhang T, Huang W Sen, Guan W, Hong Z, Gao J, Gao G, et al. Risk factors and predictors associated with the severity of COVID-19 in China: A systematic review, meta-analysis, and meta-regression. *J Thorac Dis*. 2020;12(12):7429–41.
5. Moazzami B, Chaichian S, Kasaeian A, Djalalinia S, Akhlaghdoust M, Eslami M, et al. Metabolic risk factors and risk of Covid-19: A systematic review and meta-analysis. *PLoS One [Internet]*. 2020;15(December 12):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0243600>
6. Dorjee K, Kim H, Bonomo E, Dolma R. Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients. *PLoS One [Internet]*. 2020;15(December 12):1–27. Available from: <http://dx.doi.org/10.1371/journal.pone.0243191>
7. Mesas AE, Caverro-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. *PLoS One*. 2020;15(Nov 11):1–23.
8. Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadrase O, et al. Since January 2020 Elsevier has created Predictors of mortality in patients with COVID-19—a systematic review. *Eur J Integr Med*. 2020;40:101226.
9. Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Gonçalves ANA, Ogava RLT, et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. *J Infect Dis*. 2020;222(4):556–63.
10. Hessami A, Shamsirian A, Heydari K, Pourali F, Alizadeh-Navaei R, Moosazadeh M, et al. Cardiovascular diseases burden in COVID-19: Systematic review and meta-analysis. *Am J Emerg Med [Internet]*. 2020; Available from: <https://doi.org/10.1016/j.ajem.2020.10.022>
11. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Clinical Features of COVID-19 and Factors Associated with Severe Clinical Course: A Systematic Review and Meta-Analysis. *SSRN Electron J*. 2020;
12. Meng M, Zhao Q, Kumar R, Bai C, Deng Y, Wan B. Impact of cardiovascular and metabolic diseases on the severity of COVID-19: a systematic review and meta-analysis. *Aging (Albany NY)*. 2020;12(22):23409–21.
13. Chidambaram V, Tun NL, Haque WZ, Gilbert Majella M, Kumar Sivakumar R, Kumar A, et al. Factors associated with disease severity and mortality among patients with COVID-19: A

- systematic review and meta-analysis. PLoS One [Internet]. 2020;15(Nov 11):1–29. Available from: <http://dx.doi.org/10.1371/journal.pone.0241541>
14. Parveen R, Sehar N, Bajpai R, Agarwal NB. Association of diabetes and hypertension with disease severity in covid-19 patients: A systematic literature review and exploratory meta-analysis. Diabetes Res Clin Pract [Internet]. 2020;166:108295. Available from: <https://doi.org/10.1016/j.diabres.2020.108295>
 15. Deravi N, Fathi M, Vakili K, Yaghoobpoor S, Pirzadeh M, Mokhtari M, et al. SARS-CoV-2 infection in patients with diabetes mellitus and hypertension: A systematic review. Rev Cardiovasc Med. 2020;21(3):385–97.
 16. Pillay-Van Wyk V, Bradshaw D, Groenewald P, Seocharan I, Manda S, Roomaney RA, et al. COVID-19 deaths in South Africa: 99 days since South Africa’s first death. South African Med J. 2020;110(11):1093–9.
 17. Jassat W, Cohen C, Masha M, Goldstein S, Kufa T, Savulescu D, et al. COVID-19 in-hospital mortality in South Africa: The intersection of communicable and non-communicable chronic diseases in a high HIV prevalence setting. medRxiv. 2020;
 18. Bepouka BI, Mandina M, Makulo JR, Longokolo M, Odio O, Mayasi N, et al. Predictors of mortality in covid-19 patients at Kinshasa University Hospital, Democratic Republic of the Congo, from March to June 2020. Pan Afr Med J. 2020;37(June):1–17.
 19. Kenya’s COVID-19 mortality accelerated by diabetes, hypertension - Xinhua | English.news.cn [Internet]. [cited 2021 Mar 3]. Available from: http://www.xinhuanet.com/english/2020-07/03/c_139184339.htm

BRIEF PRODUCED BY: Information Management Cell, of the WHO Regional Office IMST and the Cochrane Africa Network